Avignon, A., Radauceanu, A. and Monnier, L. (1997) Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care, 20, 1822-1826. doi:10.2337/diacare.20.12.1822

has been cited by the following article:

• TITLE: Comparison of glycemic variability between basal-bolus and premixed insulin therapy

  AUTHORS: Satoru Yamada, Ryo Hirai, Gaku Inoue, Yoshifumi Yamada, Junichiro Irie, Koichiro Atsuda, Toshikazu Yamanouchi

  KEYWORDS: Glycemic Variability; Insulin Therapy; Diabetes; Continuous Glucose Monitoring

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.3 No.2, May 9, 2013

  ABSTRACT: Background: Several studies have shown that twice-daily injections of premixed insulin analogs (MIX) could achieve comparable HbA1c levels to basal-bolus (BB) therapy. However, HbA1c does not necessarily reflect short-term glycemic fluctuations that may contribute to the onset or progression of diabetic complications. Therefore, in this study, we compared MIX and BB therapies in terms of their effects on glycemic variability. Methods: We performed a crosssectional observational study of patients attending our outpatient clinics to compare the effects of two insulin regimens on glycemic variability. We recruited patients treated with MIX or BB with HbA1c 180 mg/dL (t > 180) was significantly shorter with BB therapy (88 ± 76 min) than with MIX therapy (145 ± 54 min; p